News
Two strategic infrastructures were inaugurated this year on the bioMérieux site of La Balme-les-Grottes (Isère, France): a plastic injection unit in June and a new-generation R&D building in September. The global specialist in in vitro diagnostics is continuing its investments in France, aiming to develop new solutions for public health worldwide.
Swipe to discover more
-
bioMérieux Receives 10 Clinical Laboratory Awards for Excellence in Customer Satisfaction, System Performance and Service
bioMérieux, a world leader in in vitro diagnostics, received 10 IMV ServiceTrak™ Clinical Laboratory Awards today in the categories of microbial identification and susceptibility testing, Blood Culture, Immunoassay, and Molecular Diagnostics. The awards symbolize bioMérieux’s high-quality comprehensive customer service and system performance.
-
Diagnosing & Treating Sepsis: The Need for Speed
Reducing deaths from sepsis is directly dependent on identifying sepsis early and quickly beginning appropriate antimicrobial treatment. Fast and accurate diagnosis may also shorten the length of a hospital stay for patients and reduce the emergence of bacteria that are resistant to multiple antibiotics. -
Extremely promising clinical trial results for the high-sensitivity Point-of-Care (POC) cardiac troponin I test of our partner SpinChip Diagnostics
SpinChip Diagnostics, in which bioMérieux has held an approximate 20% stake since March 2024, has just published results showing the very good performance of its high-sensitivity Point-of-Care (POC) cardiac troponin I (hs-cTnI) assay. This innovative assay, the first of its kind, could significantly improve the diagnosis of acute myocardial infarction.
Enabling Decision-Making
- BIOMÉRIEUX ESHOP
- ANTIMICROBIAL STEWARDSHIP
- SEPSIS
- FOOD SAFETY & QUALITY
- PHARMA QUALITY CONTROL
- COVID-19
- BIOMÉRIEUX ESHOP
- ANTIMICROBIAL STEWARDSHIP
- SEPSIS
- FOOD SAFETY & QUALITY
- PHARMA QUALITY CONTROL
- COVID-19